IRCR201 also demonstrates low agonistic activity and disrupts c-Met signaling pathway activation induced by both HGF-dependent and independent mechanisms in various cancer types, eliciting distinct molecular traits compared to other c-Met-targeting antibodies. Here, MET is linked to cancer.